OncoMatch/Clinical Trials/NCT07297329

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Is NCT07297329 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SCTC21C and Bortezomib for multiple myeloma (mm).

Phase 3RecruitingSinocelltech Ltd.NCT07297329Data as of May 2026

Treatment: SCTC21C · Bortezomib · Lenalidomide · Dexamethasone — The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

adequate hematological parameters

Kidney function

adequate organ function

Liver function

adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify